Navigation Links
MiMedx Group Announces Addition of Sales Director for Europe
Date:3/9/2010

ATLANTA, March 9 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today that Karl-Matthias Moehlmann has joined the Company to lead the establishment of key distribution partners in Europe for the sales of the Company's HydroFix™ Spine Shield product. The Company was certified in Europe for design, development, and production of post-surgical adhesion inhibiting barriers, and HydroFix™ Spine Shield is indicated for use in specific locations as a cover of the spine to provide a plane of dissection during a revision surgery.  

Last week, MiMedx Group announced that it recently received the CE Mark for HydroFix™ Spine Shield, the Company's current product offering for the European market. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. The CE Mark is a mandatory conformity mark on many products placed on the market in the European Union.  The CE Mark certifies that a product conforms to the requirements of the Medical Device Directives for Europe. CE stands for Conformite Europeenne, "European Conformity" in French. The Company's product offering for the U.S. market is its HydroFix™ Vaso Shield product.  On April 20, 2009, the FDA cleared the HydroFix™ Vaso Shield, via a 510(k), as a vessel guard or cover for anterior vertebral surgery.

Parker H. "Pete" Petit, Chairman and CEO, stated, "With the addition of the CE marked HydroFix™ Spine Shield to our previously cleared HydroFix™ Vaso Shield, MiMedx is now able to market in both the U.S. and Europe.  The establishment of our relationship with Mr. Moehlmann will give us an experienced and influential partner to increase revenue through our distributors in Europe, as well as, represent MiMedx at major Euro Spine Society Meetings. He brings to the Company a wealth of experience and relationships. Mr. Moehlmann has an extensive orthopedic background with a number of leading international organizations, including Synthes Spine, Medtronic Kyphon and Depuy Spine, and he is based in Hannover, Germany. We are pleased to have Matthias as a part of the MiMedx organization."

HydroFix™ Spine Shield is only available in Europe and is not available in the United States. Conversely, HydroFix™ Vaso Shield is only available in the U.S. and is not available in Europe.

About MiMedx Group, Inc.

MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting its CollaFix™ collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the HydroFix™ Vaso Shield indicated for use as a cover for vessels following anterior spinal surgery. More information about MiMedx Group can be found at www.mimedx.com.

Important Note regarding forward-looking statements and risk factors.  This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include those regarding the effectiveness of the HydroFix™ Spine Shield in reducing the risks associated with revision surgeries, and the impact of the Company's sales director for Europe in leading the establishment of distributor partners in Europe and increasing the Company's revenues. These risks and uncertainties including, the ability of  HydroFix™ Spine Shield to perform as designed,  that the Company currently requires additional capital to survive and achieve its goals, which may be difficult or impossible to obtain, that the Company fails to establish key distributor partners in Europe and increase its revenues, that the Company may not develop additional products or receive requisite regulatory clearances and/or approvals to be able to market such  products or that such clearances or approvals may be delayed, that the Company may not be able to establish an effective distribution system for its products, and that the Company's products may not gain acceptance in the marketplace or that acceptance may be delayed.  The risks and uncertainties also include the risk factors detailed in its Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended March 31, 2009, and its most recent Form 10-Q filed on November 16, 2009.  The Company does not undertake to update its forward-looking statements.

SOURCE MiMedx Group, Inc.

Back to top

RELATED LINKS
http://www.mimedx.com

'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
2. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
7. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
8. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
9. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
10. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
11. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... 22, 2017 , ... Ecommerce sales have grown every year since the 1990’s, ... The consequences of rapid innovation and growth are often neglected in the name ... every business and individual’s job to give something back to the planet that provides ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... LAKE CITY, Utah (PRWEB) , ... April 21, ... ... provider of wilderness therapy treatment for adolescents and young adults, has kicked off ... April 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for ...
(Date:4/21/2017)... ... 2017 , ... The Patient Advocacy Community of The Beryl Institute presented Eve ... Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the field ... at The Beryl Institute’s annual Patient Experience Conference on March 20 in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... wish to overcome their mental health struggles. The Alive team uses advanced behavioral ... “Our approach in dealing with a mental health struggle is based on 10 ...
Breaking Medicine News(10 mins):